111, Inc.
YIHealthcareNASDAQMedical Distribution · Last scanned Oct 26, 2026
Scan Results
Daily timeframe111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. The $25.2M market capitalization puts YI squarely in micro-cap range for its industry. It operates through two segments, B2C and B2B.
Market Cap
$25.2M
Beta
0.67
P/E (TTM)
0.28
P/E (Fwd)
20.43
EPS (TTM)
$10.26
EPS (Fwd)
$0.14
ROE
-27.5%
ROA
-1.3%
Cash
$355.3M
Total Debt
$282.0M
Free CF
-$72.1M
52W Change
-37.0%
Annual Financials
Cash vs Debt
Where YI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, YI finished 32.47% below its 150-day moving average ($4.65) and 38.19% below its 200-day moving average ($5.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is YI overbought or oversold?
At the October 20, 2026 close, YI's RSI(14) was 21.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
111, Inc. holds $355.3M in cash against $282.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$72.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -27.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $13.52B (2022) to $12.56B (2025).
With a beta below 0.7, 111, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing YI.